Skip to main content
SpringerLink
Log in

Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis

MCP-1 im Urin als Biomarker bei Lupusnephritis: eine Metaanalyse

  • Originalien
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Ziel

Ziel der vorliegenden Studie war zu untersuchen, ob monozytenchemotaktisches Protein-1 (MCP-1) als Biomarker für die Lupusnephritis (LN) dienen könnte.

Methoden

Es wurde eine Metaanalyse durchgeführt, um den Zusammenhang zwischen dem MCP-1-Wert und LN anhand dreier Vergleiche zu untersuchen: aktive LN vs. inaktive LN, aktive LN vs. Kontrollen und inaktive LN vs. Kontrollen.

Ergebnisse

Für diese Metaanalyse standen 8 Studien mit insgesamt 399 Patienten mit LN (204 mit aktiver LN und 195 mit inaktiver LN) und 130 Kontrollen zur Verfügung. Es zeigte sich in der Metaanalyse, dass der MCP-1-Wert im Urin in der Gruppe mit aktiver LN signifikant höher als in der Gruppe mit inaktiver LN war (standardisierte Mittelwertsdifferenz, SMD: 1,883; 95 %-KI: 0,811–2,954; p = 0,001). Die Metaanalyse ergab auch, dass der MCP-1-Wert im Urin in der Gruppe mit aktiver LN signifikant höher als in der Kontrollgruppe war (SMD: 3,085; 95 %-KI: 1,684–4,485; p = 1,6 × 10−5). Darüber hinaus zeigte sich bei Stratifizierung nach Ethnizität ein signifikant erhöhter MCP-1-Wert in der Gruppe mit aktiver LN bei Kaukasiern, Asiaten und Ägyptern (SMD: 2,408; 95 %-KI: 1,711–3,105; p < 1,0 × 10−8; SMD: 1,020; 95 %-KI: 0,623–2,153; p = 4,6 × 10−7 bzw. SMD: 7,370; 95 %-KI: 1,467–2,157; p = 5,9 × 10−5). Anhand der Metaanalyse war auch festzustellen, dass der MCP-1-Wert im Urin in der Gruppe mit inaktiver LN signifikant höher als in der Kontrollgruppe war (SMD: 1,812; 95 %-KI: 0,628–2,996; p = 0,003).

Schlussfolgerung

Aus der Metaanalyse ergab sich, dass der MCP-1-Wert im Urin bei Patienten mit aktiver LN signifikant höher als bei Patienten mit inaktiver LN und bei den Kontrollen war. Die Patienten mit inaktiver LN wiesen signifikant höhere MCP-1-Werte im Urin auf als die Kontrollen.

Abstract

Objective

This study aimed to evaluate whether urinary monocyte chemoattractant protein-1 (MCP-1) could serve as a biomarker for lupus nephritis (LN).

Methods

We performed a meta-analysis to examine the relationship between urinary MCP-1 level and LN in three comparisons: active LN versus inactive LN, active LN versus control, and inactive LN versus control.

Results

Eight studies of a total of 399 patients with LN (204 with active LN, and 195 with inactive LN) and 130 controls were available for this meta-analysis. The meta-analysis revealed that the urinary MCP-1 level was significantly higher in the active-LN group than in the inactive-LN group (standard mean difference [SMD] = 1.883, 95 % confidence interval [CI] = 0.811–2.954, p = 0.001). The meta-analysis showed that the urinary MCP-1 level was significantly higher in the active-LN group than in the control group (SMD = 3.085, 95 % CI = 1.684–4.485, p = 1.6 × 10−5). Furthermore, stratification by ethnicity showed significantly elevated urinary MCP-1 levels in the active-LN group in Caucasian, Asian, and Egyptian populations (SMD = 2.408, 95 % CI = 1.711–3.105, p < 1.0 × 10−8; SMD = 1.020, 95 % CI = 0.623–2.153, p = 4.6 × 10−7; and SMD = 7.370, 95 % CI = 1.467–2.157, p = 5.9 × 10−5, respectively). The meta-analysis indicated that the urinary MCP-1 level was also significantly higher in the inactive-LN group than in the control group (SMD = 1.812, 95 % CI = 0.628–2.996, p = 0.003).

Conclusions

The meta-analysis demonstrated that urinary MCP-1 was significantly higher in patients with active LN than in those with inactive LN and control subjects, and the patients with inactive LN showed significantly higher urinary MCP-1 levels than the controls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Waldman M, Appel GB (2006) Update on the treatment of lupus nephritis. Kidney Int 70:1403–1412

    Article  CAS  PubMed  Google Scholar 

  2. Zubiria Salgado A de, Herrera-Diaz C (2012) Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012:1–21. doi:10.1155/2012/849684

    Article  Google Scholar 

  3. Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 29:313–326

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Alharazy S, Kong NC, Mohd M, Shah SA, Ba’in A, Gafor AAH (2015) Urine monocyte chemoattractant protein-1 and lupus nephritis disease activity: preliminary report of a prospective longitudinal study. Autoimmune Dis 2015:1–13. doi:10.1155/2015/962046

    Article  Google Scholar 

  5. Wada T, Furuichi K, Segawa-Takaeda C et al (1999) MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56:995–1003

    Article  CAS  PubMed  Google Scholar 

  6. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I (1997) An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 186:131–137

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mok CC (2010) Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010:1–11. doi:10.1155/2010/638413

    Article  Google Scholar 

  8. Wada T, Yokoyama H, Su SB et al (1996) Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 49:761–767

    Article  CAS  PubMed  Google Scholar 

  9. Ghobrial EE, El Hamshary AA, Mohamed AG, Abd El Raheim YA, Talaat AA (2015) Urinary monocyte chemoattractant protein-1 as a biomarker of lupus nephritis activity in children. Saudi J Kidney Dis Transpl 26:507–515

    Article  PubMed  Google Scholar 

  10. Susianti H, Iriane VM, Dharmanata S et al (2015) Analysis of urinary TGF-beta1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology 22:65–71

    Article  CAS  PubMed  Google Scholar 

  11. Rosa RF, Takei K, Araujo NC, Loduca SM, Szajubok JC, Chahade WH (2012) Monocyte chemoattractant-1 as a urinary biomarker for the diagnosis of activity of lupus nephritis in brazilian patients. J Rheumatol 39:1948–1954

    Article  CAS  PubMed  Google Scholar 

  12. Xuejing Z, Jiazhen T, Jun L, Xiangqing X, Shuguang Y, Fuyou L (2012) Urinary TWEAK level as a marker of lupus nephritis activity in 46 cases. J Biomed Biotechnol 2012:1–7. doi:10.1155/2012/359647

    Article  Google Scholar 

  13. Watson L, Midgley A, Pilkington C et al (2012) Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus. Lupus 21:496–501

    Article  CAS  PubMed  Google Scholar 

  14. El-Shehaby A, Darweesh H, El-Khatib M et al (2011) Correlations of urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and IL-8 with lupus nephritis. J Clin Immunol 31:848–856

    Article  CAS  PubMed  Google Scholar 

  15. Noris M, Bernasconi S, Casiraghi F et al (1995) Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis. Lab Invest 73:804–809

    CAS  PubMed  Google Scholar 

  16. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus 19:703–710

    Article  CAS  PubMed  Google Scholar 

  17. Lee YH, Woo JH, Choi SJ, Ji JD, Song GG (2010) Associations between osteoprotegerin polymorphisms and bone mineral density: a meta-analysis. Mol Biol Rep 37:227–234

    Article  CAS  PubMed  Google Scholar 

  18. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wells G, Shea B, O’connell D et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Eur J Epidemiol 25(9):603–605

    Google Scholar 

  20. Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315:1533–1537

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    Article  CAS  PubMed  Google Scholar 

  22. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558

    Article  PubMed  Google Scholar 

  23. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Duval S, Tweedie R (2000) Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455–463

    Article  CAS  PubMed  Google Scholar 

  25. Illei GG, Tackey E, Lapteva L, Lipsky PE (2004) Biomarkers in systemic lupus erythematosus. I. general overview of biomarkers and their applicability. arthritis and rheumatism. Arthritis Care Res 50:1709–1720

    Article  CAS  Google Scholar 

  26. Nowling TK, Gilkeson GS (2011) Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 13:250

    Article  PubMed  PubMed Central  Google Scholar 

  27. Rovin BH, Song H, Birmingham DJ, Hebert LA, Yu CY, Nagaraja HN (2005) Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 16:467–473

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Internal Medicine, Korea University Medical Center, Korea University College of Medicine, 73 Inchon-ro, Seongbuk-gu, 02841, Seoul, Korea

    Y. H. Lee & G. G. Song

Authors
  1. Y. H. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. G. Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. H. Lee.

Ethics declarations

Conflict of interest

Y. H. Lee and G. G. Song state that there are no conflicts of interest.

The accompanying manuscript does not include studies on humans or animals.

Additional information

Redaktion

U. Müller-Ladner, Bad Nauheim

U. Lange, Bad Nauheim

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, Y.H., Song, G.G. Urinary MCP-1 as a biomarker for lupus nephritis: a meta-analysis. Z Rheumatol 76, 357–363 (2017). https://doi.org/10.1007/s00393-016-0109-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-016-0109-z

Schlüsselwörter

Keywords

Search

Navigation